<DOC>
	<DOCNO>NCT00276718</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , etoposide , carboplatin , bleomycin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Giving chemotherapy drug surgery may make tumor small reduce amount normal tissue need remove . Giving combination chemotherapy surgery may kill tumor cell remain . PURPOSE : This clinical trial study well give etoposide , carboplatin , bleomycin work treat young patient undergo surgery malignant germ cell tumor .</brief_summary>
	<brief_title>Etoposide , Carboplatin , Bleomycin Treating Young Patients Undergoing Surgery For Malignant Germ Cell Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxic effect etoposide , carboplatin , bleomycin young patient malignant germ cell tumor . OUTLINE : Patients assign one two treatment arm base tumor type ( testicular v ovarian , uterine , vaginal , sacrococcygeal , retroperitoneal , thoracic ) . - Group 1 ( testicular tumor ) : Patients undergo radical orchiectomy . Patients stage I tumors alpha-fetoprotein ( AFP ) decrease expect rate receive treatment unless subsequent rise AFP clinical recurrence . Patients stage II-IV tumor receive etoposide IV 1 hour day 1-3 , carboplatin IV 1 hour day 2 , bleomycin IV 15 minute day 3 . Treatment repeat every 21- 28 day least 4 course absence disease progression unacceptable toxicity . Residual teratoma may remove , indicate , completion chemotherapy . - Group 2 ( ovarian , uterine , vaginal , sacrococcygeal , retroperitoneal , thoracic germ cell tumor ) : Patients undergo surgical removal biopsy tumor . Patients receive etoposide , carboplatin , bleomycin . Patients may undergo surgery discretion principal investigator . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 100 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove malignant germ cell tumor stag Testicular tumor Stage I Confined testis Stage II Confined testes retroperitoneal/abdominal lymph node Stage III Supradiaphragmatic nodal disease ( mediastinal and/or supraclavicular ) Stage IV Extralymphatic spread ( liver , lung , bone , brain , skin , etc . ) Ovarian , uterine , vaginal , sacrococcygeal tumor Stage I Confined ovary/uterus/vagina/pre postsacral area Stage II Spread limit pelvis Stage III Spread limit abdomen ( exclude liver ) Stage IV Spread liver beyond abdominal cavity Abdominal , retroperitoneal , thoracic primary tumor Stage I Confined site origin resectable Stage II Local spread Stage III Extensive spread confine one side diaphragm ( exclude liver ) Stage IV Tumor spread liver , side diaphragm , and/or bone , bone marrow , brain , etc . Intracranial germ cell tumor case allow even alternative protocol follow PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : No prior chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>childhood malignant ovarian germ cell tumor</keyword>
	<keyword>childhood malignant testicular germ cell tumor</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>childhood extragonadal germ cell tumor</keyword>
	<keyword>childhood teratoma</keyword>
</DOC>